论文部分内容阅读
目的:探究难治性消化性溃疡患者通过胶体果胶铋兰索拉唑与康复新液四联治疗后取得的临床成效。方法:选取我院收治的难治性消化性溃疡患者80例,且均在2014年1月-2016年6月入院,依随机分组标准分为观察组(40人)和对照组(40人)。对照组治疗方法为胶体果胶铋、兰索拉唑、甲硝唑及阿莫西林治疗,观察组患者在胶体果胶铋、兰索拉唑、甲硝唑及阿莫西林治疗的基础上联合康复新液治疗。从临床治疗有效率方面入手,针对相关内容进行分析。结果:对照组治疗总有效率(77.5%)比观察组(92.5%)低(P<0.05)。结论:难治性消化性溃疡患者通过胶体果胶铋兰索拉唑与康复新液四联治疗后取得的临床成效显著,能够有效提高治疗效果,存在一定推广价值。
Objective: To investigate the clinical efficacy of refractory peptic ulcer patients treated by quadruple colloidal pectin bismuth lansoprazole and kangfuxin solution. Methods: Eighty patients with refractory peptic ulcer admitted in our hospital were enrolled. All patients were admitted to our hospital from January 2014 to June 2016. According to the standard of randomization, the patients were divided into observation group (40 persons) and control group (40 persons) . The control group of treatment for colloidal bismuth pectin, lansoprazole, metronidazole and amoxicillin treatment, the observation group of patients in colloidal pectin bismuth, lansoprazole, metronidazole and amoxicillin treatment based on the combination Rehabilitation of new liquid treatment. Starting from the clinical treatment efficiency, analysis of the relevant content. Results: The total effective rate of the control group (77.5%) was lower than that of the observation group (92.5%) (P <0.05). CONCLUSION: The clinical results of refractory peptic ulcer patients achieved by quadruple colloidal pectin bismuth lansoprazole and kangfuxin solution are significant, which can effectively improve the therapeutic effect and have some popularization value.